A BILL 
To improve patient access to emerging medication therapies 
by clarifying the scope of permitted health care economic 
and scientific information communications between bio-
pharmaceutical manufacturers and population health de-
cision makers, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pre-approval Informa-
4
tion Exchange Act of 2022’’. 
5
03:54 Mar 11, 2022
H7008
2 
•HR 7008 IH
SEC. 2. FACILITATING EXCHANGE OF INFORMATION PRIOR 
1
TO APPROVAL. 
2
Section 502(a) of the Federal Food, Drug, and Cos-
3
metic Act (21 U.S.C. 352(a)) is amended— 
4
(1) by redesignating subparagraph (2) as sub-
5
paragraph (3); 
6
(2) by inserting after subparagraph (1) the fol-
7
lowing: 
8
‘‘(2)(A) Health care economic information, scientific 
9
information, or product support information provided to 
10
a covered payor responsible for the selection of drugs or 
11
devices for coverage, reimbursement, or other population- 
12
based health care management, shall not be considered 
13
false or misleading or any other form of misbranding 
14
under this section or a violation of section 505, 510(k), 
15
513, or 515 of this Act or section 351 of the Public Health 
16
Service Act, or otherwise prohibited pre-approval pro-
17
motion of a drug or device, if it— 
18
‘‘(i)(I) in the case of health care economic in-
19
formation, is based on competent and reliable sci-
20
entific evidence; or 
21
‘‘(II) in the case of scientific information other 
22
than health care economic information, is truthful 
23
and nonmisleading; and 
24
‘‘(ii) relates to an investigational drug or device 
25
or investigational use of a drug or device that is ap-
26
03:54 Mar 11, 2022
H7008
3 
•HR 7008 IH
proved, cleared, or licensed under section 505, 
1
510(k), 513, or 515 of this Act or section 351 of the 
2
Public Health Service Act (as applicable). 
3
‘‘(B) In order to provide information pursuant to this 
4
subparagraph relating to an investigational drug or device, 
5
or an investigational use of an drug or device that has 
6
been approved, granted marketing authorization, cleared, 
7
or licensed— 
8
‘‘(i) the information must include— 
9
‘‘(I) a clear statement that the investiga-
10
tional drug or device or investigational use of a 
11
drug or device has not been approved, cleared, 
12
or licensed under section 505, 510(k), 513, or 
13
515 of this Act or section 351 of the Public 
14
Health Service Act (as applicable) and that the 
15
safety and effectiveness of the drug or device or 
16
use has not yet been established; 
17
‘‘(II) information related to the stage of 
18
development of the drug or device involved, 
19
such as— 
20
‘‘(aa) the status of any study or stud-
21
ies in which the investigational drug or de-
22
vice or investigational use is being inves-
23
tigated; 
24
03:54 Mar 11, 2022
H7008
4 
•HR 7008 IH
‘‘(bb) how the study or studies relate 
1
to the overall plan for the development of 
2
the drug or device; 
3
‘‘(cc) whether a marketing application 
4
or notification for the investigational drug 
5
or device or investigational use has been 
6
submitted to the Secretary and when such 
7
a submission is planned; 
8
‘‘(III) in the case of communications that 
9
include factual presentations of results from 
10
studies, a description of— 
11
‘‘(aa) material aspects of study de-
12
sign, methodology, and results; and 
13
‘‘(bb) material limitations related to 
14
the study design, methodology, and results; 
15
and 
16
‘‘(IV) where applicable, a conspicuous and 
17
prominent statement describing any material 
18
differences between the information provided 
19
and the labeling approved, granted marketing 
20
authorization, cleared, or licensed pursuant to 
21
section 505, 510(k), 513, or 515 of this Act or 
22
section 351 of the Public Health Service Act. 
23
‘‘(C) For purposes of this subparagraph— 
24
03:54 Mar 11, 2022
H7008
5 
•HR 7008 IH
‘‘(i) the term ‘covered payor’ means a payor, 
1
formulary committee, drug information center, tech-
2
nology assessment committee, pharmacy benefit 
3
manager, and other multidisciplinary entity that, on 
4
behalf of health care organizations, reviews scientific 
5
or technology assessments, or other similar entity 
6
with knowledge and expertise to evaluate health care 
7
economic analysis or scientific information on a pop-
8
ulation basis; 
9
‘‘(ii) the term ‘product support information’ in-
10
cludes— 
11
‘‘(I) information describing the drug or de-
12
vice (such as drug class, device description, and 
13
features); 
14
‘‘(II) information about the indication or 
15
indications sought; 
16
‘‘(III) the anticipated timeline for a pos-
17
sible approval, clearance, or licensure pursuant 
18
to section 505, 510(k), 513, or 515 of this Act 
19
or section 351 of the Public Health Service Act; 
20
‘‘(IV) drug or device pricing information; 
21
‘‘(V) patient utilization projections; and 
22
‘‘(VI) product-related programs or services. 
23
‘‘(iii) the term ‘scientific information’ includes 
24
clinical and pre-clinical data and results relating to 
25
03:54 Mar 11, 2022
H7008
6 
•HR 7008 IH
a drug or device or use that has not been approved, 
1
granted marketing authorization, cleared, or licensed 
2
and is being investigated or developed.’’; 
3
(3) in subparagraph (3), as redesignated— 
4
(A) by striking ‘‘(A)’’; 
5
(B) by striking clause (B); and 
6
(C) by striking ‘‘drug’’ each place it ap-
7
pears and inserting ‘‘drug or device’’; and 
8
(4) by adding at the end the following: 
9
‘‘(4) Nothing in this section shall be construed to 
10
limit the ability of manufacturers or sponsors of drugs or 
11
devices to engage in communications or activities not spec-
12
ified in subparagraph (2) or (3) that are otherwise permis-
13
sible.’’. 
14
SEC. 3. GAO STUDY AND REPORT. 
15
Beginning on the date that is 5 years and 6 months 
16
after the date of enactment of this Act, the Comptroller 
17
General of the United States (in this subsection referred 
18
to as the ‘‘Comptroller General’’) shall conduct a study 
19
on the provision and use of information pursuant to sec-
20
tion 502(a)(2) of the Federal Food, Drug, and Cosmetic 
21
Act, as added by section 2 of this Act, between manufac-
22
turers of, and covered entities (as defined in such section 
23
502(a)(2)) for, drugs and devices (as defined in section 
24
201 of the Federal Food, Drug, and Cosmetic Act (21 
25
03:54 Mar 11, 2022
H7008
7 
•HR 7008 IH
U.S.C. 321)). Such study shall include an analysis of the 
1
following: 
2
(1) The type of information communicated be-
3
tween such manufacturers and payors. 
4
(2) The manner of communication between 
5
such manufacturers and payors. 
6
(3)(A) Whether such manufacturers file a sub-
7
mission for approval, marketing authorization, clear-
8
ance, or licensing of a new drug or device or the new 
9
use of a drug or device that is the subject of commu-
10
nication between such manufacturers and payors be-
11
fore the new use is approved, granted marketing au-
12
thorization, cleared, or licensed. 
13
(B) How frequently the Food and Drug Admin-
14
istration approves, grants marketing authorization, 
15
clears, or licenses the new drug or device or new use. 
16
(C) The timeframe between the initial commu-
17
nications under section 502(a) of the Federal Food, 
18
Drug, and Cosmetic Act, as amended by this Act, 
19
regarding an investigational drug or device or inves-
20
tigational use, and the initial marketing of such 
21
drug or device or investigational use. 
22
Æ 
03:54 Mar 11, 2022
H7008
